Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses.

Sanyal C, Husereau DR.

Value Health. 2019 Dec;22(12):1450-1457. doi: 10.1016/j.jval.2019.08.013. Epub 2019 Nov 4. Review.

PMID:
31806202
2.

Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists.

Sanyal C, Husereau D.

Appl Health Econ Health Policy. 2019 Nov 21. doi: 10.1007/s40258-019-00535-x. [Epub ahead of print] Review.

PMID:
31755015
3.

Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer.

Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schunemann H, Guyatt G, Xie F.

MDM Policy Pract. 2019 Aug 13;4(2):2381468319852594. doi: 10.1177/2381468319852594. eCollection 2019 Jul-Dec.

4.

Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists.

Sanyal C, Husereau DR, Beahm NP, Smyth D, Tsuyuki RT.

BMC Health Serv Res. 2019 Jul 18;19(1):499. doi: 10.1186/s12913-019-4303-y.

5.

A Beginner's Guide to Understanding Curative Therapies.

Husereau D, Reed SD.

Value Health. 2019 Jun;22(6):619-620. doi: 10.1016/j.jval.2019.04.1910. No abstract available.

PMID:
31198177
6.

Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario.

Jetty P, Husereau D, Kansal V, Zhang T, Nagpal S.

J Vasc Surg. 2019 Nov;70(5):1469-1478. doi: 10.1016/j.jvs.2019.01.091. Epub 2019 May 27.

PMID:
31147121
7.

Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries.

Husereau D, Nason E, Ahuja T, Nikaï E, Tsakonas E, Jacobs P.

Int J Technol Assess Health Care. 2019 Jan;35(3):181-188. doi: 10.1017/S0266462319000291. Epub 2019 May 28.

PMID:
31133089
8.

Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).

Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schunemann H, Guyatt G.

Med Decis Making. 2019 May;39(4):370-378. doi: 10.1177/0272989X19837969. Epub 2019 Mar 22.

PMID:
30902030
9.

Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA.

Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, Augustovski F, Booth A, Bridges JFP, Grimshaw J, IJzerman MJ, Jonsson E, Ollendorf DA, Rüther A, Siebert U, Sharma J, Wailoo A.

Value Health. 2019 Jan;22(1):13-20. doi: 10.1016/j.jval.2018.08.010. Epub 2018 Dec 13.

PMID:
30661627
10.

Evidence and its impact on pharmacy practice: Don't be "evidence-illiterate".

Sanyal C, Husereau D, Tsuyuki RT.

Can Pharm J (Ott). 2018 Oct 11;151(6):357-358. doi: 10.1177/1715163518805404. eCollection 2018 Nov-Dec. No abstract available.

11.

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review.

Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X.

Eur Respir J. 2018 Nov 29;52(5). pii: 1801393. doi: 10.1183/13993003.01393-2018. Print 2018 Nov.

12.

Economic evaluations of eHealth technologies: A systematic review.

Sanyal C, Stolee P, Juzwishin D, Husereau D.

PLoS One. 2018 Jun 13;13(6):e0198112. doi: 10.1371/journal.pone.0198112. eCollection 2018.

13.

Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data.

Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A.

Allergy Asthma Clin Immunol. 2018 Apr 24;14:15. doi: 10.1186/s13223-018-0241-1. eCollection 2018.

14.

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.

Husereau D, Feagan B, Selya-Hammer C.

Appl Health Econ Health Policy. 2018 Jun;16(3):279-288. doi: 10.1007/s40258-018-0371-0.

15.

Guidelines for reporting health economic evaluation studies.

Silva END, Silva MT, Augustovski F, Husereau D, Pereira MG.

Epidemiol Serv Saude. 2017 Oct-Dec;26(4):895-898. doi: 10.5123/S1679-49742017000400020. English, Portuguese. No abstract available.

16.

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Beca J, Husereau D, Chan KKW, Hawkins N, Hoch JS.

Pharmacoeconomics. 2018 Jan;36(1):7-15. doi: 10.1007/s40273-017-0583-4.

PMID:
29110141
17.

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?-ERRATUM.

Husereau D, Henshall C, Sampietro-Colom L, Thomas S.

Int J Technol Assess Health Care. 2016 Jan;32(6):407. doi: 10.1017/S0266462316000659. Epub 2017 Jan 9.

PMID:
28065169
18.

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?

Husereau D, Henshall C, Sampietro-Colom L, Thomas S.

Int J Technol Assess Health Care. 2016 Jan;32(4):191-199. Epub 2016 Oct 21. Erratum in: Int J Technol Assess Health Care. 2016 Jan;32(6):407.

PMID:
27766998
19.

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P.

Clin Pharmacol. 2016 Aug 11;8:93-107. doi: 10.2147/CPAA.S105165. eCollection 2016.

20.

Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.

Tawfik A, Wodchis WP, Pechlivanoglou P, Hoch J, Husereau D, Krahn M.

Appl Health Econ Health Policy. 2016 Jun;14(3):313-22. doi: 10.1007/s40258-016-0229-2.

PMID:
26924098
21.

David Sackett 1934-2015.

Drummond M, Husereau D.

Value Health. 2015 Jul;18(5):549. doi: 10.1016/j.jval.2015.06.001. Epub 2015 Jul 22. No abstract available.

22.

Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Internet].

Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Mar.

23.

MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS.

Akpinar I, Jacobs P, Husereau D.

Int J Technol Assess Health Care. 2015 Jan;31(1-2):86-9. doi: 10.1017/S026646231500015X. Epub 2015 May 20.

PMID:
25989920
24.

How do we value a cure?

Husereau D.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):551-5. doi: 10.1586/14737167.2015.1039519. Epub 2015 Apr 27.

PMID:
25915098
25.

Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration.

Husereau D, Drummond M, Petrou S, Greenberg D, Mauskopf J, Augustovski F, Briggs AH, Moher D, Loder E, Carswell C.

Pharmacoeconomics. 2015 May;33(5):535-6. doi: 10.1007/s40273-015-0277-8. No abstract available.

PMID:
25893576
26.

Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.

Husereau D, Dempster W, Blanchard A, Chambers J.

Value Health. 2014 Dec;17(8):888-94. doi: 10.1016/j.jval.2014.08.2673. Epub 2014 Nov 4.

27.

How do economic evaluations inform health policy decisions for treatment and prevention in Canada and the United States?

Husereau D, Culyer AJ, Neumann P, Jacobs P.

Appl Health Econ Health Policy. 2015 Jun;13(3):273-9. doi: 10.1007/s40258-014-0133-6.

PMID:
25316309
28.

Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle.

Manns B, Braun T, Edwards A, Grimshaw J, Hemmelgarn B, Husereau D, Ivers N, Johnson J, Long S, McBrien K, Naugler C, Sargious P, Straus S, Tonelli M, Tricco AC, Yu C; Alberta Innovates; Health Solutions Interdisciplinary Chronic Disease Collaboration.

CMAJ Open. 2013 Nov 20;1(4):E142-50. doi: 10.9778/cmajo.20130024. eCollection 2013 Oct.

29.

Incorporating economic evaluation into immunization decision making in Canada: a workshop.

Langley JM, Krahn M, Husereau D, Spika J, Fisman DN, Chit A, Van Exan R.

Expert Rev Vaccines. 2014 Nov;13(11):1291-6. doi: 10.1586/14760584.2014.939637. Epub 2014 Jul 23. No abstract available.

30.

Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices.

Husereau D, Henshall C, Jivraj J.

Int J Technol Assess Health Care. 2014 Jul;30(3):241-9. doi: 10.1017/S0266462314000191. Epub 2014 Jun 12.

PMID:
24921416
31.

Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?

Husereau D, Marshall DA, Levy AR, Peacock S, Hoch JS.

Int J Technol Assess Health Care. 2014 Apr;30(2):179-87. doi: 10.1017/S0266462314000142. Epub 2014 May 7.

PMID:
24806420
32.

A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

Berger ML, Martin BC, Husereau D, Worley K, Allen JD, Yang W, Quon NC, Mullins CD, Kahler KH, Crown W.

Value Health. 2014 Mar;17(2):143-56. doi: 10.1016/j.jval.2013.12.011. Erratum in: Value Health. 2014 Jun;17(4):489.

33.

A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Manns B.

PLoS One. 2014 Mar 11;9(3):e90434. doi: 10.1371/journal.pone.0090434. eCollection 2014. Review.

34.

A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.

Barnieh L, Manns B, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Clement F.

Value Health. 2014 Jan-Feb;17(1):98-108. doi: 10.1016/j.jval.2013.10.008.

35.

Lista de Comprobación CHEERS en Españ̆ol: Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias.

Husereau D.

Value Health Reg Issues. 2013 Dec;2(3):335-337. doi: 10.1016/j.vhri.2013.08.002. Epub 2013 Dec 12. No abstract available.

PMID:
29702766
36.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

Int J Technol Assess Health Care. 2013 Apr;29(2):117-22. doi: 10.1017/S0266462313000160. Epub 2013 Apr 15.

PMID:
23587340
37.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

BJOG. 2013 May;120(6):765-70. doi: 10.1111/1471-0528.12241.

38.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

Value Health. 2013 Mar-Apr;16(2):e1-5. doi: 10.1016/j.jval.2013.02.010.

39.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force.

Value Health. 2013 Mar-Apr;16(2):231-50. doi: 10.1016/j.jval.2013.02.002.

40.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

Clin Ther. 2013 Apr;35(4):356-63. doi: 10.1016/j.clinthera.2013.03.003. Epub 2013 Mar 25.

PMID:
23537754
41.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

Cost Eff Resour Alloc. 2013 Mar 25;11(1):6. doi: 10.1186/1478-7547-11-6.

42.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

BMC Med. 2013 Mar 25;11:80. doi: 10.1186/1741-7015-11-80.

43.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

BMJ. 2013 Mar 25;346:f1049. doi: 10.1136/bmj.f1049.

44.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E.

Pharmacoeconomics. 2013 May;31(5):361-7. doi: 10.1007/s40273-013-0032-y.

PMID:
23529207
45.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E.

Eur J Health Econ. 2013 Jun;14(3):367-72. doi: 10.1007/s10198-013-0471-6.

PMID:
23526140
46.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.

J Med Econ. 2013;16(6):713-9. doi: 10.3111/13696998.2013.784591. Epub 2013 Mar 25.

PMID:
23521434
47.

Trends in the utilization of endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures in Canada.

Jetty P, Husereau D.

J Vasc Surg. 2012 Dec;56(6):1518-26, 1526.e1. doi: 10.1016/j.jvs.2012.05.102. Epub 2012 Oct 13.

48.

Wait times among patients with symptomatic carotid artery stenosis requiring carotid endarterectomy for stroke prevention.

Jetty P, Husereau D, Kubelik D, Nagpal S, Brandys T, Hajjar G, Hill A, Sharma M.

J Vasc Surg. 2012 Sep;56(3):661-7.e1-2. doi: 10.1016/j.jvs.2012.03.001. Epub 2012 May 16.

49.

Guidelines for health technologies: specific guidance for oncology products in Canada.

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl NB, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Taylor SC, Jacobs P, Oh PI.

Value Health. 2012 May;15(3):580-5. doi: 10.1016/j.jval.2011.12.006. Epub 2012 Feb 16.

50.

The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies.

Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D.

Int J Technol Assess Health Care. 2012 Apr;28(2):138-44. doi: 10.1017/S0266462312000086. Review.

PMID:
22559755

Supplemental Content

Loading ...
Support Center